Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 1 de 1
1.
Front Endocrinol (Lausanne) ; 15: 1386510, 2024.
Article En | MEDLINE | ID: mdl-38665263

In hypothyroid patients needing large doses of levothyroxine (L-T4) (>1.7-2 µg/kg/day) to reach euthyroidism, lactose intolerance (LI) needs to be excluded, owing to the high prevalence in the population. If LI is present, a lactose-free diet decreases the rate of L-T4 malabsorption. However, an increased requirement of L-T4 is described in patients with LI, which can be beneficially treated using lactose-free L-T4 formulation. The lactose-free liquid L-T4 formulation is able to circumvent LI malabsorption leading to the normalization of thyroid-stimulating hormone (TSH) in patients with subclinical hypothyroidism and long-term stable TSH levels.


Hypothyroidism , Lactose Intolerance , Thyroxine , Humans , Lactose Intolerance/drug therapy , Thyroxine/therapeutic use , Thyroxine/pharmacokinetics , Hypothyroidism/drug therapy , Hypothyroidism/metabolism , Lactose , Female , Malabsorption Syndromes/drug therapy , Malabsorption Syndromes/metabolism , Male , Middle Aged , Thyrotropin/blood , Thyrotropin/metabolism , Adult
...